Results of our flow cytometry analysis of dissociated cell suspensions from patient-derived tumor samples indicated that 16 mg/kg PG2 significantly increased the population of CD45+ leucocytes/white blood cells (WBCs) (3.02-fold, p < 0.001), which coincidentally seems to be due to a significant 9.4% expansion of the CD45+CD8+ T cells (p < 0.01), with no apparently significant variation in the number of CD4+ T cells in PG2-treated tumor samples compared to their untreated counterparts (Supplementary Figure S2). Here, PTPRC is linked to neoplasm.